Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-05 21:02 | 2026-06-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Khan Najat | Director, Officer | SELL | $3.58 | 23,588 | $84,459 | 2,175,796 |
| 2026-06-05 21:03 | 2026-06-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Director | SELL | $3.62 | 40,000 | $144,800 | 883,735 |
| 2026-06-05 20:32 | 2026-06-03 | EDIT | Editas Medicine, Inc. | Burkly Linda | Officer | SELL | $2.70 | 731 | $1,975 | 67,297 |
| 2026-06-05 20:33 | 2026-06-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | Director, Officer | SELL | $2.70 | 15,380 | $41,543 | 248,313 |
| 2026-06-05 20:33 | 2026-06-03 | EDIT | Editas Medicine, Inc. | Parison Amy | Officer | SELL | $2.70 | 464 | $1,253 | 14,970 |
| 2026-06-04 20:05 | 2026-06-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer | OPT+S | $35.00 | 4,375 | $153,125 | 75,753 |
| 2026-06-04 22:02 | 2026-06-02 | NBIX | NEUROCRINE BIOSCIENCES INC | Cooke Julie | Officer | OPT+S | $156.22 | 36,937 | $5,770,235 | 22,374 |
| 2026-06-04 21:04 | 2026-06-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Borgeson Blake | Director | SELL | $3.68 | 30,000 | $110,400 | 6,169,863 |
| 2026-06-04 21:04 | 2026-06-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Bumpus Namandje | Director | SELL | $3.54 | 4,386 | $15,526 | 43,171 |
| 2026-06-03 20:59 | 2026-06-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | Officer | SELL | $49.52 | 2,250 | $111,416 | 158,494 |
| 2026-06-04 00:30 | 2026-06-01 | REPL | Replimune Group, Inc. | Sarchi Christopher | Officer | SELL | $9.24 | 12,000 | $110,880 | 180,962 |
| 2026-06-04 00:06 | 2026-06-01 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer | OPT+S | $67.40 | 50,000 | $3,370,010 | 767,780 |
| 2026-06-03 22:51 | 2026-06-01 | EXEL | EXELIXIS, INC. | Eckhardt Sue Gail | Director | SELL | $50.14 | 9,812 | $491,974 | 16,079 |
| 2026-06-03 22:52 | 2026-06-01 | EXEL | EXELIXIS, INC. | WYSZOMIERSKI JACK L | Director | SELL | $50.55 | 3,925 | $198,409 | 284,384 |
| 2026-06-03 22:03 | 2026-06-02 | OTLK | Outlook Therapeutics, Inc. | Haddadin Yezan Munther | Director | BUY | $0.83 | 29,000 | $24,145 | 66,167 |
| 2026-06-03 21:30 | 2026-06-02 | ALEC | Alector, Inc. | Berkley Neil Lindsay | Officer | SELL | $1.97 | 19,360 | $38,221 | 379,900 |
| 2026-06-03 21:30 | 2026-06-02 | ALEC | Alector, Inc. | Wong-Sarad Grace | Officer | SELL | $1.94 | 9,184 | $17,813 | 95,461 |
| 2026-06-03 21:30 | 2026-06-02 | ALEC | Alector, Inc. | Rosenthal Arnon | Director, Officer | SELL | $1.97 | 87,216 | $172,191 | 2,367,206 |
| 2026-06-03 21:01 | 2026-06-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer | OPT+S | $25.66 | 14,853 | $381,112 | 0 |
| 2026-06-03 21:04 | 2026-06-01 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | Director, Officer | SELL | $26.20 | 6,643 | $174,048 | 27,970 |
| 2026-06-02 20:12 | 2026-05-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | Officer | OPT+S | $26.34 | 7,500 | $197,554 | 24,808 |
| 2026-06-02 20:05 | 2026-06-01 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Director, Officer | SELL | $19.44 | 5,466 | $106,253 | 594,538 |
| 2026-06-02 20:05 | 2026-05-29 | TWST | Twist Bioscience Corp | Cho Dennis | Officer | SELL | $69.75 | 14,205 | $990,799 | 120,094 |
| 2026-06-02 20:05 | 2026-05-29 | TWST | Twist Bioscience Corp | Laponis Adam | Officer | SELL | $70.00 | 4,000 | $280,000 | 112,675 |
| 2026-06-02 20:05 | 2026-06-01 | FENC | FENNEC PHARMACEUTICALS INC. | Raykov Rosty | Director | OPT+S | $9.62 | 9,747 | $93,766 | 130,079 |
| 2026-06-02 22:08 | 2026-06-01 | NBIX | NEUROCRINE BIOSCIENCES INC | Onyia Jude | Officer | OPT+S | $160.25 | 11,000 | $1,762,710 | 25,846 |
| 2026-06-02 22:03 | 2026-05-29 | NBIX | NEUROCRINE BIOSCIENCES INC | Delaet Ingrid | Officer | OPT+S | $156.71 | 2,261 | $354,321 | 16,225 |
| 2026-06-02 22:04 | 2026-06-01 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer | SELL | $131.46 | 15,000 | $1,971,846 | 617,567 |
| 2026-06-02 21:35 | 2026-06-01 | VIR | Vir Biotechnology, Inc. | Napolitano Janet | Director | SELL | $9.45 | 3,200 | $30,240 | 21,216 |
| 2026-06-02 21:20 | 2026-06-01 | HALO | HALOZYME THERAPEUTICS, INC. | Connaughton Bernadette | Director | SELL | $66.21 | 1,625 | $107,591 | 43,669 |
| 2026-06-02 21:31 | 2026-06-01 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | Officer | SELL | $9.45 | 379 | $3,582 | 61,902 |
| 2026-06-02 20:48 | 2026-06-01 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | Director, Officer | SELL | $10.02 | 1,922 | $19,258 | 1,057,231 |
| 2026-06-01 20:05 | 2026-05-29 | GLUE | Monte Rosa Therapeutics, Inc. | Townson Sharon | Officer | OPT+S | $19.87 | 6,000 | $119,220 | 67,845 |
| 2026-06-01 20:05 | 2026-05-28 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer | OPT+S | $67.91 | 16,470 | $1,118,555 | 846,872 |
| 2026-06-01 20:05 | 2026-05-28 | TWST | Twist Bioscience Corp | Starovasnik Melissa A. | Director | SELL | $68.00 | 2,500 | $170,000 | 22,222 |
| 2026-06-02 01:30 | 2026-05-28 | OTLK | Outlook Therapeutics, Inc. | Sukhtian Ghiath M. | Director, 10% owner | BUY | $0.59 | 8,539,709 | $5,000,000 | 22,092,068 |
| 2026-06-01 21:35 | 2026-05-29 | CRSP | CRISPR Therapeutics AG | Patel Naimish | Officer | OPT+S | $55.62 | 3,786 | $210,577 | 19,357 |
| 2026-05-29 20:04 | 2026-05-28 | IMVT | Immunovant, Inc. | Fromkin Andrew J. | Director | OPT+S | $33.51 | 221,951 | $7,438,111 | 74,382 |
| 2026-05-29 23:21 | 2026-05-27 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.90 | 73,738 | $434,715 | 2,604,107 |
| 2026-05-29 22:09 | 2026-05-27 | NBIX | NEUROCRINE BIOSCIENCES INC | Onyia Jude | Officer | OPT+S | $155.53 | 11,000 | $1,710,865 | 25,846 |
| 2026-05-28 20:10 | 2026-05-26 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | Officer | OPT+S | $153.99 | 3,121 | $480,611 | 54,400 |
| 2026-05-28 20:05 | 2026-05-26 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer | OPT+S | $65.19 | 49,299 | $3,213,654 | 846,872 |
| 2026-05-28 20:05 | 2026-05-26 | TWST | Twist Bioscience Corp | WERNER ROBERT F. | Officer | SELL | $62.48 | 800 | $49,987 | 48,186 |
| 2026-05-28 20:05 | 2026-05-26 | TWST | Twist Bioscience Corp | Starovasnik Melissa A. | Director | SELL | $61.04 | 500 | $30,520 | 24,722 |
| 2026-05-28 20:05 | 2026-05-27 | ADMA | ADMA BIOLOGICS, INC. | Grossman Jerrold B | Director | BUY | $7.91 | 6,400 | $50,624 | 520,284 |
| 2026-05-28 20:12 | 2026-05-27 | ATYR | aTYR PHARMA INC | SCHIMMEL PAUL | Director | BUY | $0.50 | 100,000 | $49,630 | 779,143 |
| 2026-05-28 23:10 | 2026-05-27 | GLUE | Monte Rosa Therapeutics, Inc. | Champoux Jennifer | Officer | OPT+S | $20.00 | 2,175 | $43,500 | 62,371 |
| 2026-05-28 22:25 | 2026-05-26 | EXEL | EXELIXIS, INC. | Aftab Dana | Officer | SELL | $50.35 | 43,451 | $2,187,758 | 594,741 |
| 2026-05-28 22:08 | 2026-05-26 | NBIX | NEUROCRINE BIOSCIENCES INC | Boyer David W. | Officer | SELL | $156.64 | 3,888 | $609,023 | 7,799 |
| 2026-05-28 20:34 | 2026-05-11 | ARTV | Artiva Biotherapeutics, Inc. | GC Corp. | 10% owner | BUY | $11.52 | 1,432,291 | $16,499,992 | 1,607,734 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.